FDA Brief

Warning letters Devices

FDA warning letter to

Fresenius Medical Care AG & Co. KGaA

High riskIssued Dec 4, 2023Posted Dec 19, 2023Center for Devices and Radiological Health

FDA warns Fresenius over delayed fixes and reporting for PCB leaching from silicone tubing in hemodialysis machines.

What happened

FDA inspected Fresenius Medical Care Holdings in Waltham, Massachusetts, from June 26 to August 2, 2023, and found quality-system violations for its 2008 series hemodialysis machines. FDA said the company waited almost two years after learning in December 2020 about PCB emissions from peroxide-crosslinked silicone tubing before opening a corrective action and recalling the devices in November 2022. FDA also found inadequate PCB risk assessment, incomplete CAPA records, flawed design validation, and a field correction not reported within 10 working days.

What FDA found

  1. Fresenius waited almost two years after learning in December 2020 about PCB emissions from silicone tubing before opening a corrective and preventive action (CAPA) in June 2022, and did not recall the devices until November 2022.

    21 CFR 820.100(a)
  2. Its health hazard assessment for PCB leaching did not include the 20 kg minimum body weight listed in the instructions for use.

    21 CFR 820.100(a)
  3. It did not verify that corrective actions were effective for a CAPA tied to a recall for a false 'Remove USB 2 Device' alarm on 2008T and 2008T Bluestar machines.

    21 CFR 820.100(a)
  4. CAPA 1100660 did not document all activities, including the first awareness of the PCB finding, action plans, and corrections to distributed devices.

    21 CFR 820.100(b)
  5. FDA found the company did not follow its design validation procedure when checking whether the 2008 T, 2008 K, and 2008 K2 machines could be used safely and effectively; the studies also had protocol problems, including one protocol not approved before use.

    21 CFR 820.30(g)
  6. A field correction begun on November 25, 2022, to change silicone tubing was not reported in writing to FDA within 10 working days.

    21 CFR 806.10(b)

What FDA wants

FDA asks Fresenius to respond in writing within 15 business days with specific corrective steps, supporting documentation, and how it will prevent recurrence; if actions will take longer, provide a timetable. FDA also asks for status updates on the open CAPAs.

Who should pay attention

  • dialysis clinics and patients using Fresenius 2008 series machines
  • medical device manufacturers with CAPA, complaint, and recall-reporting duties
  • suppliers of silicone tubing and other patient-contact components

This is a summary. Read the original letter on fda.gov.

Fresenius Medical Care AG & Co. KGaA's FDA history

  1. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk

Full company page

Similar letters to other companies

  1. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk